Cliramitug (NI-006; ALXN2220) is a monoclonal antibody that targets human transthyretin ( TTR ). Cliramitug binds to TTR and inhibits its amyloidogenic process, exerting amyloid formation-inhibiting activity. Cliramitug can be used in the research of transthyretin amyloidosis-related diseases, such as certain neurological and cardiovascular diseases [1].
In Vitro, Cliramitug accelerates phagocyte-mediated clearance of dense-structured ATTR amyloid fibrils in vitro[1].
References:
[1]. Pillai AA, et al. Antibody ALXN2220 (Formerly NI006) for the Treatment of Transthyretin Cardiac Amyloidosis. Cardiol Rev. Published online April 22, 2025.
In Vitro, Cliramitug accelerates phagocyte-mediated clearance of dense-structured ATTR amyloid fibrils in vitro[1].
References:
[1]. Pillai AA, et al. Antibody ALXN2220 (Formerly NI006) for the Treatment of Transthyretin Cardiac Amyloidosis. Cardiol Rev. Published online April 22, 2025.